Podcasts

OncLive On Air^® is a podcast from OncLive^® that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays.

Wainberg Weighs In on Advances in HER2+ GI Cancers

July 12th 2021

Dr. Wainberg discusses factors that help steer treatment selection in HER2-positive gastrointestinal malignancies, advances on the horizon, and more.

CTCA Leaders Provide Post-Pandemic Predictions in Oncology

July 8th 2021

Dr. Rariy, Ms. Brown, and Ms. Greenman discuss how the COVID-19 pandemic has led to a significant delay in cancer diagnoses, impacted the training of oncologists, and revolutionized telehealth.

Research Reflections: O'Malley Relays Key Updates in Ovarian and Endometrial Cancers

July 5th 2021

Dr. O’Malley discusses key findings from 6 trials that were presented at the virtual 2021 SGO Annual Meeting on Women’s Cancer.

Sherman Spotlights Advances With RET Inhibitors in Medullary Thyroid Cancer

July 1st 2021

Dr. Sherman discusses the incidence of RET fusions in medullary thyroid cancer and the current clinical landscape of RET inhibitors in the field.

Lee-Kim on Fostering a Fulfilling Fellowship in Oncology

June 28th 2021

Dr. Lee-Kim discusses her path into treating pediatric patients with cancer, key lessons that can be learned during fellowship, and tips on managing finances and burnout during a pediatric oncology fellowship program.

Halmos Highlights Effort Exploring COVID-19 Vaccines in Patients With Cancer

June 24th 2021

Dr. Halmos discusses the data from a study examining seroconversion rates following COVID-19 vaccination among patients with cancer and underscores the need for novel vaccination or passive immunization strategies for immunosuppressed cohorts.

Matsen Reflects on Changes to Breast Cancer Surgery During COVID-19

June 21st 2021

Dr. Masten reflects on the main challenges that arose during the COVID-19 lockdown with regard to surgery in patients with breast cancer, the steps that were taken as the lockdown started to lift, and the changes that have been made with regard to managing patients around the time of surgery and in the operating room.

George Gives Take on Optimal Sequencing, Strategies in Pancreatic Cancer Pipeline

June 17th 2021

Dr. George discusses treatment considerations in the first-line setting of metastatic pancreatic cancer, signs that may indicate disease progression and the need for second-line therapy, and investigational agents in the pipeline.

Pant Projects an Expanding Role for Targeted Therapy in Pancreatic Cancer

June 14th 2021

Dr. Pant discusses the current role for germline and somatic testing in pancreatic cancer, examines the research landscape with PARP inhibitors, KRAS inhibitors, and other targeted agents, and shares his hope for the future of drug development in the field.

Patel Previews Collaborative Research Program With SD-101 in Uveal Melanoma

June 10th 2021

Dr. Patel discusses the significance of the new collaboration between The University of Texas MD Anderson Cancer Center and TriSalus™ Life Sciences.

Advances in Metastatic HER2-Positive Breast Cancer

June 8th 2021

Dr Gradishar and colleagues highlight key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

Treating Early-Stage HER2-Positive Breast Cancer

June 8th 2021

Dr Gradishar and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Examining the Unmet Needs in the Treatment of HER2-Positive Breast Cancer

June 8th 2021

In the first segment, Dr Gradishar and colleagues examine the unmet needs clinicians face despite recent advances in the treatment of patients with HER2-positive breast cancer.

FDA Approval Insights: Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma

June 7th 2021

Dr. Munshi discusses the significance of the FDA approval of ide-cel in relapsed/refractory multiple myeloma, data from the KarMMa trial, which served as the basis for the approval, and next steps for CAR T-cell therapy in the field.

FDA Approval Insights: Tivozanib in Relapsed/Refractory Advanced RCC

June 3rd 2021

Dr. Rini discusses unique elements of the TIVO-3 trial, the significance of the FDA approval of tivozanib in advanced RCC, and potential next steps for research with the TKI in the paradigm.

Landgren Breaks Down the Benefit of Novel Quadruplet in Newly Diagnosed Myeloma

May 31st 2021

Dr. Landgren discusses the potential of a quadruplet regimen comprised of carfilzomib, lenalidomide, dexamethasone, and daratumumab in the treatment of patients with newly diagnosed multiple myeloma.

Baumann Characterizes the Current Treatment Landscape of Merkel Cell Carcinoma

May 27th 2021

Dr. Baumann sheds light on the incidence, prognosis, and treatment of patients with Merkel cell carcinoma, ongoing clinical research, and strategies to raise awareness for this rare disease.

Treatment of Advanced HER2-Positive Breast Cancer

May 27th 2021

Dr Jhaveri and colleagues highlight key clinical trials in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

Treatment of Early-Stage HER2-Positive Breast Cancer

May 27th 2021

Dr Jhaveri and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Unmet Needs in the Treatment of HER2-Positive Breast Cancer

May 27th 2021

In the first segment, Dr Jhaveri and colleagues discuss the unmet needs clinicians face in the treatment of patients with HER2-positive breast cancer.